CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Marcia Belvin Sells 19,512 Shares of Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Marcia Belvin sold 19,512 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total transaction of $11,707.20. Following the sale, the senior vice president now directly owns 248,636 shares in the company, valued at $149,181.60. This trade represents a 7.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

CytomX Therapeutics Trading Down 0.6 %

NASDAQ:CTMX opened at $0.67 on Friday. The company has a 50-day moving average price of $0.77 and a 200-day moving average price of $0.99. CytomX Therapeutics, Inc. has a 12 month low of $0.56 and a 12 month high of $5.85. The stock has a market cap of $53.34 million, a price-to-earnings ratio of 3.92 and a beta of 1.05.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.45. The company had revenue of $38.09 million during the quarter, compared to analyst estimates of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. Equities analysts forecast that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

Institutional Trading of CytomX Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Formidable Asset Management LLC grew its stake in shares of CytomX Therapeutics by 55.5% in the fourth quarter. Formidable Asset Management LLC now owns 382,529 shares of the biotechnology company’s stock worth $394,000 after acquiring an additional 136,528 shares during the period. Velan Capital Investment Management LP purchased a new position in shares of CytomX Therapeutics in the fourth quarter worth $36,000. Tidal Investments LLC lifted its holdings in shares of CytomX Therapeutics by 55.5% in the fourth quarter. Tidal Investments LLC now owns 382,529 shares of the biotechnology company’s stock worth $394,000 after buying an additional 136,528 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of CytomX Therapeutics in the fourth quarter worth $2,730,000. Finally, Prosight Management LP increased its position in CytomX Therapeutics by 29.2% in the fourth quarter. Prosight Management LP now owns 3,905,000 shares of the biotechnology company’s stock worth $4,022,000 after purchasing an additional 882,891 shares during the last quarter. 67.77% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

CTMX has been the topic of a number of analyst reports. StockNews.com raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, March 10th. Wedbush reissued an “outperform” rating and issued a $5.00 price target on shares of CytomX Therapeutics in a report on Friday, March 7th. Finally, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, March 7th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $5.02.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.